Counselling framework for moderate-penetrance cancer-susceptibility mutations
暂无分享,去创建一个
Mark E. Robson | Susan M. Domchek | Kenneth Offit | Fergus Couch | Zsofia Stadler | Judy E. Garber | F. Couch | K. Offit | K. Nathanson | J. Garber | M. Robson | N. Tung | Z. Stadler | S. Domchek | Katherine L. Nathanson | Nadine Tung
[1] S. Bojesen,et al. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Knudson. Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.
[3] Daniel J. Park,et al. Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers. , 2014, Cancer discovery.
[4] Michele L Cote,et al. BRCA1, BRCA2, PALB2, and CDKN2A Mutations in Familial Pancreatic Cancer (FPC): A PACGENE Study , 2014, Genetics in Medicine.
[5] M. Yaffe,et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Lihong Liu,et al. The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. , 2013, DNA and cell biology.
[7] M. Robson,et al. CHEK2, breast cancer, and the understanding of clinical utility , 2009, Clinical genetics.
[8] Deborah Hughes,et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer , 2011, Nature Genetics.
[9] Guofeng Zhang,et al. Significant association between Nijmegen breakage syndrome 1 657del5 polymorphism and breast cancer risk , 2013, Tumor Biology.
[10] Tom Walsh,et al. Inherited Mutations in Women With Ovarian Carcinoma. , 2016, JAMA oncology.
[11] Karla Bowles,et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next‐generation sequencing with a 25‐gene panel , 2015, Cancer.
[12] S. Cross,et al. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Kenneth Offit,et al. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.
[14] Yuya Kobayashi,et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Rosalind Eeles,et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.
[16] A. Whittemore,et al. Practical Problems With Clinical Guidelines for Breast Cancer Prevention Based on Remaining Lifetime Risk , 2015, Journal of the National Cancer Institute.
[17] A. Børresen-Dale,et al. Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. , 2010, Journal of the National Cancer Institute.
[18] Herb Chen,et al. Is intraoperative parathyroid hormone monitoring necessary with ipsilateral parathyroid gland visualization during anticipated unilateral exploration for primary hyperparathyroidism: a two-institution analysis of more than 2,000 patients. , 2014, Surgery.
[19] Rochelle L. Garcia,et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing , 2011, Proceedings of the National Academy of Sciences.
[20] Daniel J. Park,et al. A PALB2 mutation associated with high risk of breast cancer , 2010, Breast Cancer Research.
[21] Brigitte Rack,et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Hopper,et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.
[23] Aniruddh Kashyap,et al. Germline RECQL mutations are associated with breast cancer susceptibility , 2015, Nature Genetics.
[24] D. Easton,et al. Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants , 2013, Journal of Medical Genetics.
[25] Anthony J. Guidi,et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions , 2012, Breast Cancer Research and Treatment.
[26] Nazneen Rahman,et al. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. , 2004, American journal of human genetics.
[27] J. Martens,et al. Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases. , 2013, European journal of cancer.
[28] P. Ang,et al. Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.
[29] L. Kiemeney,et al. CHEK2*1100delC homozygosity in the Netherlands—prevalence and risk of breast and lung cancer , 2013, European Journal of Human Genetics.
[30] S. Syngal,et al. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome. , 2015, Gastroenterology.
[31] Lara E Sucheston-Campbell,et al. Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] A. Børresen-Dale,et al. Variants in the ATM gene associated with a reduced risk of contralateral breast cancer. , 2008, Cancer research.
[33] G. Petersen,et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. , 2015, Gastroenterology.
[34] Angela DeMichele,et al. Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2 negative patients with early onset breast cancer , 2014, Genetics in Medicine.
[35] Yuchen Jiao,et al. ATM mutations in patients with hereditary pancreatic cancer. , 2012, Cancer discovery.
[36] Kenneth Offit,et al. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. , 2005, Human molecular genetics.
[37] M. Yaffe,et al. American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007 .
[38] D. Oram,et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial , 2016, The Lancet.
[39] Tina Pesaran,et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients , 2014, Genetics in Medicine.
[40] Fan Wang,et al. APC polymorphisms and the risk of colorectal neoplasia: a HuGE review and meta-analysis. , 2013, American journal of epidemiology.
[41] angesichts der Corona-Pandemie,et al. UPDATE , 1973, The Lancet.
[42] Yuya Kobayashi,et al. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. , 2015, JAMA oncology.
[43] A. W. van der Vaart,et al. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women , 2011, Journal of Medical Genetics.
[44] Lesley McGuffog,et al. Cancer risks and mortality in heterozygous ATM mutation carriers. , 2005, Journal of the National Cancer Institute.
[45] M. Goodman,et al. Analysis of CHEK2 gene for ovarian cancer susceptibility. , 2004, Gynecologic oncology.
[46] kConFab investigators,et al. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing , 2016 .
[47] T. Pal,et al. Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory , 2014, Clinical genetics.
[48] J. Reis-Filho,et al. Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] A. Gylfason,et al. Mutations in BRIP1 confer high risk of ovarian cancer , 2011, Nature Genetics.
[50] R. Warren,et al. Differences in Natural History between Breast Cancers in BRCA1 and BRCA2 Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined , 2012, Cancer Epidemiology, Biomarkers & Prevention.
[51] H. D. de Koning,et al. Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC) , 2015, International journal of cancer.
[52] N. Harbeck,et al. Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer – Chapter B: Prevention, Early Detection, Lifestyle, Premalignant Lesions, DCIS, Recurrent and Metastatic Breast Cancer , 2010, Breast Care.
[53] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[54] A. Stuckey,et al. ACR Appropriateness Criteria® Breast Cancer Screening. , 2017, Journal of the American College of Radiology : JACR.
[55] Nazneen Rahman,et al. Gene-panel sequencing and the prediction of breast-cancer risk. , 2015, The New England journal of medicine.
[56] K. Offit,et al. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] W. Zheng,et al. Genetic variants associated with colorectal cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence , 2013, Gut.
[58] L. Esserman,et al. Genetic/familial high-risk assessment , 2010 .
[59] A. Meindl,et al. Germline RAD51C mutations confer susceptibility to ovarian cancer , 2012, Nature Genetics.
[60] K. Offit,et al. Time to check CHEK2 in families with breast cancer? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] R. Houlston,et al. A systematic review and meta-analysis of familial colorectal cancer risk , 2001, American Journal of Gastroenterology.
[62] A. Whittemore,et al. Population‐based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066–6T>G (IVS10–6T>G) from the Breast Cancer Family Registry , 2006, Human mutation.
[63] B. Monk,et al. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2. , 2014, Gynecologic oncology.
[64] Yuya Kobayashi,et al. A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and 77 78 79 80 81 82 Ovarian Cancer Genes in More Than 1000 Patients , 2015 .
[65] E. Feuer,et al. SEER Cancer Statistics Review, 1975-2003 , 2006 .
[66] A. Gylfason,et al. Loss-of-function variants in ATM confer risk of gastric cancer , 2015, Nature Genetics.
[67] G. Valk,et al. Breast-cancer predisposition in multiple endocrine neoplasia type 1. , 2014, The New England journal of medicine.
[68] D. Plewes,et al. Systematic Review: Using Magnetic Resonance Imaging to Screen Women at High Risk for Breast Cancer , 2008, Annals of Internal Medicine.